Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival

[Reuters] – Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Statistically significant improvement in overall survival was the secondary . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival Similar Articles: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fighting drug Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis